Clinical Trials Logo
  1. Home
  2. Relapsed Ovarian Cancer
  3. NCT04887961

Reprab Study: PLD + Trabectedin Rechallenge — MITO36  

Relapsed Ovarian Cancer Clinical Trial

Official title:
Rechallenge With PLD Added to Trabectedine in Recurrent Ovarian Cancer: a Multicenter Prospective Trial

Clinical Trial Summary

RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL

Clinical Trial Description

To demonstrate that rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (Yondelis®) is active (objective response rate) in relapsed ovarian cancer patients who have already received pegylated liposomal doxorubicin and progress within 6-12 months after the end of last platinum or in fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04887961
Study type Interventional
Source Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Giovanni Scambia, PI
Phone 0630153250
Email Giovanni.scambia@policlinicogemelli.it
Status Recruiting
Phase Phase 2
Start date October 1, 2020
Completion date April 1, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01874353 - Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Phase 3
Not yet recruiting NCT06081595 - Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment Phase 2
Recruiting NCT04517357 - A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients Phase 2
Active, not recruiting NCT03534453 - Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy Phase 3
Recruiting NCT05080556 - Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Phase 2
Recruiting NCT05607329 - Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial N/A
Terminated NCT04999605 - A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer Phase 1/Phase 2
Completed NCT02825420 - Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
Recruiting NCT04713514 - OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC Phase 2
Not yet recruiting NCT05479487 - Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment Phase 2